PeptideOS
← Library

Vasopressin

Hormone

Also known as: Arginine vasopressin, AVP, Antidiuretic hormone, ADH, Vasostrict

Tier 1, Approved, characterised

Approved by at least one major regulator for a defined indication, with published human pharmacokinetics and a prescribing label. Well-characterised does not mean risk-free, read the label warnings.

Half-life
10.0 minutes · human data · intravenous

Vasostrict FDA label: elimination half-life is <=10 minutes (<=0.167 h) at infusion rates used in vasodilatory shock.

Model a dosing schedule →
Dosing
No established dose

Dosed in units/minute, not micrograms. Label: post-cardiotomy shock 0.03-0.1 units/min; septic shock 0.01-0.07 units/min; general guidance 0.01-0.1 units/min, titrate to lowest effective dose. Kept in original units.

Frequency
Continuous IV infusion (must be diluted before use)
Regulatory status
FDA-approved (Vasostrict, vasopressin injection USP) to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
Evidence base
human clinical · confidence: high

FDA-approved with a modern regulated label; high-quality data for the shock indication.

Storage

Reconstituted: Store 2°C-8°C (36°F-46°F); do not freeze. Unopened vials may be held at 20°C-25°C for up to 12 months within shelf life. After first puncture of the 10 mL vial, refrigerate and discard after 30 days.

Safety

No FDA boxed warning. Label warns of reversible diabetes insipidus on discontinuation, and that extravasation can cause skin/tissue necrosis; use with caution given potent vasoconstriction (risk of reduced cardiac output, mesenteric/coronary/distal ischemia).

Sources